Dominic Mailänder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominic Mailänder has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- András Tálas
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
1 shared publication - Charles D. Yeh
Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH Zurich), Zurich, Switzerland
1 shared publication - Christelle Chanez
Department of Biochemistry, University of Zurich, Zurich, Switzerland
1 shared publication - Gerald Schwank
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
1 shared publication - Isabelle F. Harvey-Seutcheu
Department of Biochemistry, University of Zurich, Zurich, Switzerland
1 shared publication - Jacob Ellery Corn
Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Top Cited Papers
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eadz1884
Programmable genome editing in human cells using RNA-guided bridge recombinases
Site-specific insertion of gene-sized DNA fragments remains an unmet need in the field of genome editing. IS110-family serine recombinases have recently been shown to mediate programmable DNA recombination in bacteria by using a bispecific RNA guide (bridge RNA) that simultaneously recognizes target and donor sites. In this work, we have shown that the bridge recombinase ISCro4 is highly active in human cells and provided structural insights into its enhanced activity. Using plasmid- or all-RNA–based delivery, ISCro4 supports programmable multikilobase excisions and inversions and facilitates donor DNA insertion at genomic sites with efficiencies that exceed 6%. Last, we assessed ISCro4 specificity and off-target activity. These results establish a framework for the development of bridge recombinases as next-generation tools for editing modalities that are beyond the capabilities of current technologies.
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eadz1884
Top Cited PapersProgrammable genome editing in human cells using RNA-guided bridge recombinases
Site-specific insertion of gene-sized DNA fragments remains an unmet need in the field of genome editing. IS110-family serine recombinases have recently been shown to mediate programmable DNA recombination in bacteria by using a bispecific RNA guide (bridge RNA) that simultaneously recognizes target and donor sites. In this work, we have shown that the bridge recombinase ISCro4 is highly active in human cells and provided structural insights into its enhanced activity. Using plasmid- or all-RNA–based delivery, ISCro4 supports programmable multikilobase excisions and inversions and facilitates donor DNA insertion at genomic sites with efficiencies that exceed 6%. Last, we assessed ISCro4 specificity and off-target activity. These results establish a framework for the development of bridge recombinases as next-generation tools for editing modalities that are beyond the capabilities of current technologies.